Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | CLK1 | P49759 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491221 | 0.85 | GSK3B (0.60) | GSK3BKDM4EALDH1A1 | |
| SCHEMBL3491483 | 0.84 | GSK3B (0.52) | GSK3BMEN1KMT2ANPC1CLK1 | |
| SCHEMBL3517190 | 0.78 | KMT2A (0.54) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL338133 | 0.77 | CYP4F2 (0.51) | NPC1CLK1RAB9APOLB | |
| SCHEMBL3493598 | 0.77 | GSK3B (0.54) | GSK3BNPC1RAB9AMAPK1HTT | |
| SCHEMBL3491930 | 0.75 | GSK3B (0.61) | GSK3BNPC1RAB9AALDH1A1 | |
| SCHEMBL18392699 | 0.73 | RAB9A (0.56) | KMT2ANPC1CLK1RAB9AKDM4E | |
| SCHEMBL28987831 | 0.73 | SMN1; SMN2 (0.62) | NPC1RAB9ASMN1; SMN2KDM4EGAA | |
| SCHEMBL15540789 | 0.71 | NPC1 (0.66) | GSK3BMEN1KMT2ANPC1CLK1 | |
| SCHEMBL15117500 | 0.71 | GSK3B (0.47) | GSK3BNPC1CLK1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | GSK3B 1/4885MEN1 1680/4885KMT2A 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.